The United States Eventing Association Names Zomedica’s PulseVet(R) as the Official Shock Wave of the USEA
Zomedica will sponsor a variety of high-profile events within the USEA ANN ARBOR, MI / ACCESSWIRE / July 17, 2024...
Healthcare
REMSleep Holdings Inc. Announces Strategic Marketing Plan for DELTAWAVE Nasal Pillows System
CLEARWATER, Fla., July 17, 2024 (GLOBE NEWSWIRE) -- REMSleep Holdings Inc. (OTCQB: RMSL), a pioneer in sleep apnea treatment solutions,...
On Heels of Family Forward NC Certification, Aeroflow Health Will Employ a Record 900 in Coming Months
ASHEVILLE, N.C., July 17, 2024 (GLOBE NEWSWIRE) -- Aeroflow Health announced today that it has made its 850th hire and...
Bon Secours Mercy Health and Philips sign multi-year strategic collaboration
Doctor monitoring patient health July 17, 2024 Patient monitoring platform to deliver tools and time to help patients across 40+...
What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk
New Nationwide Survey Findings Show That More Than Half of Women Do Not Know That Breast Density Can Reveal Increased...
HealthLynked Expands Telemedicine Nationwide
NAPLES, Fla., July 17, 2024 (GLOBE NEWSWIRE) -- via IBN – HealthLynked Corp. (OTCQB: HLYK), a global leader in healthcare...
MIMEDX to Host Second Quarter 2024 Operating and Financial Results Conference Call on July 31
MARIETTA, Ga., July 17, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that...
Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer’s Disease
Wa'el Hashad Wa'el Hashad, CEO, Longeveron – FDA designation enables expedited clinical development and regulatory review timelines for Lomecel-B™ – –...
Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024
Pepinemab is believed to block astrocyte reactivity, a key pathology driving Alzheimer’s progressionROCHESTER, N.Y., July 17, 2024 (GLOBE NEWSWIRE) --...
Oxford Biomedica announces CFO transition
Oxford Biomedica announces Chief Financial Officer transition - Lucinda Crabtree to join as Chief Financial Officer - Oxford, UK –...
Fortrea Announces Date for Second Quarter 2024 Financial Results and Conference Call
DURHAM, N.C., July 17, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO),...
Draupnir Bio completes €12 million seed round to progress development of oral small molecule degraders of extracellular proteins
Draupnir Bio completes €12 million seed round to progress development of oral small molecule degraders of extracellular proteins MP Healthcare...
Ancilia Biosciences Announces Closing of $4.2 Million Financing
Supports Development of Ancilia’s Unique Platform that Harnesses CRISPR’s Natural Function to Increase the Utility of Live Bacterial Products for Therapeutic...
Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting
- 6E10 combined with local prophylaxis selected for Phase 3 pivotal trials, with a favorable safety profile and potential best-in-class...
EssilorLuxottica signs an agreement to acquire a majority stake in Heidelberg Engineering and continues to make moves in the med-tech space
EssilorLuxottica signs an agreement to acquire a majority stake in Heidelberg Engineering and continues to make moves in the med-tech space...
ONWARD® Medical Publishes Annual Sustainability Summary
Company strengthens sustainability practices prior to commercializationEINDHOVEN, the Netherlands, July 17, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD),...
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity
After four weeks of treatment, CT-996 demonstrated clinically meaningful weight loss of -7.3% (weight loss in placebo -1.2%; p <...
CORRECTION — Onco360 Selected as a Limited Distribution Specialty Pharmacy Partner for Rytelo™ (imetelstat)
In a release issued under the same headline on July 12, 2024 by Onco360 Oncology Pharmacy, please note the change...
Subtle Medical Receives FDA-Clearance for Industry First AI-powered Synthetic Imaging Software, SubtleSYNTH™
Subtle Medical's new software is now available for clinical use in the US, further redefining the speed and quality of...
Senderra Specialty Pharmacy introduces a groundbreaking digital solution, SenderraCare+. This innovative solution revolutionizes the patient’s journey for specialty therapy medications
SenderraCare+ is a game-changer for providers and patients alike. It simplifies the time-consuming process and offers a real-time digital solution...